Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nas

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nas

WARREN, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Dr. Neal Flomenberg and Dr. Lori Grosso of Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, discussed the promise of T cell therapy and Tevogen’s mission to make it mainstream on Nasdaq’s broadcast, Live From MarketSite with Kristina Ayanian.

ONLY AVAILABLE IN PAID PLANS

Published by: globenewswire

Read full article here: https://www.globenewswire.com/news-release/2024/07/10/2911088/0/en/Tevogen-Bio-s-R-D-Leadership-Discusses-The-Promise-of-Its-Genetically-Unmodified-Off-The-Shelf-T-Cell-Technology-For-The-Treatment-of

  • Nasdaq:tvgnw
  • Us88165K1016
  • Nasdaq:tvgn
  • Health
  • United States Of America
Primedice

© BitNe. All Rights Reserved. Designed by HTML Codex

>